Haemonetics (HAE) Fundamentals 2026 — P/E 37.8x, Revenue Analysis | SniperIQ
Haemonetics (HAE) is a US-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of
Haemonetics (HAE) is a US-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of
Haemonetics (HAE) has a market capitalization of approximately
Haemonetics's trailing twelve-month P/E ratio is 37.8x, with a price-to-book (P/B) of 4.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Haemonetics runs a net profit margin of 7.3%, a gross margin of 57.3%, and an operating margin of 18.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Haemonetics reported revenue of
Haemonetics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Haemonetics carries a debt-to-equity ratio of 1.54x and a current ratio of 2.95x, with a market beta of 0.52. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Haemonetics (HAE) the key facts are: market cap
Get Haemonetics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.